Ordering
Available Variants5 mg
CHA.77527-5mg
Price
€71.92
Available – Dispatch in 14 days
25 mg
CHA.77527-25mg
Price
€288.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.77527-5mg | €71.92 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.77527-25mg | €288.80 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C15H22N2O4 |
|---|---|
| CAS Number | 1418033-25-6 |
| Molecular Weight | 294.35 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 |
| pcodes | P264 - P270 - P301 + P312 - P501 |
| Hazard Classifications | Acute Tox. 4 Oral |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
LMK235, also known by its CAS number 1418033-25-6, is a potent and selective inhibitor of protein kinase B (PKB), also referred to as Akt. This compound has been extensively studied for its potential therapeutic applications, particularly in the treatment of various types of cancer. LMK235 has been shown to effectively suppress the activity of Akt, a key enzyme involved in cell survival and proliferation pathways. By inhibiting Akt, LMK235 can induce apoptosis and inhibit cell growth in cancer cells, making it a promising candidate for cancer therapy. Further research is needed to fully explore the potential of LMK235 as a therapeutic agent and to investigate its efficacy and safety in clinical settings. Its unique mechanism of action and selective inhibition of Akt make LMK235 an interesting compound for ongoing research in the field of oncology.
